Morgan Stanley Downgrades DOC to Hold, Sets $22 Price Target

On June 11, 2026, Morgan Stanley analyst Richard Hill downgraded DOC to a hold rating and set a price target of $22. This change reflects a more cautious outlook on the company's stock.

Other Institutional Activity in DOC

Several other institutional investors have adjusted their positions in DOC. BlackRock, Inc. slightly reduced its holdings by 182,068 shares, ending with 73,360,519 shares valued at about $1.21 billion. Vanguard Portfolio Management LLC established a new position with 58,125,899 shares worth approximately $955 million. State Street Corp trimmed its stake by 872,866 shares, leaving it with 48,500,600 shares valued at roughly $797 million. Meanwhile, JPMorgan Chase & Co significantly increased its holdings by 14,056,729 shares, totaling 44,731,541 shares worth around $740 million.

DOC Stock Snapshot

Shares of DOC traded near $20.69. The stock has been under the spotlight with significant institutional movements and analyst ratings adjustments.

Insider Buying and Selling at Healthpeak Properties, Inc.

Recent insider transactions at DOC include several notable movements. On May 29, 2026, EVP and Treasurer Ankit Patadia bought 1,358 shares at $15.46 per share and sold 94 shares at $19.15. Chief Financial Officer Kelvin Moses also purchased 937 shares at $15.46. Additionally, President and CEO Scott Brinker sold 114 shares at $19.15.

Analysts Set New Price Targets

On June 11, 2026, Morgan Stanley downgraded DOC to a hold rating with a $22 price target. Previously, on June 1, Wells Fargo maintained a hold rating with a $20 target, and on May 27, Scotiabank also maintained a hold with a $21 target. These ratings reflect a generally cautious stance among analysts.

About DOC

DOC is a company operating in the healthcare sector, providing services and solutions related to healthcare real estate. The company is known for its strategic management of healthcare facilities, offering a range of services to healthcare providers. DOC is headquartered in the United States and focuses on creating value through its real estate investments.

Bottom Line

Morgan Stanley's downgrade of DOC to a hold rating with a $22 target highlights a shift in sentiment. The stock's recent trading activity, along with insider transactions, provides additional context for investors. As always, remember that these analyst ratings and institutional moves are backward-looking and may not reflect the current market conditions.